GHRP-6 Injection

Growth hormone deficiency (GHD) is a disease caused by insufficient secretion of growth hormone by the pituitary gland, characterized by symptoms such as short stature and growth retardation. By stimulating the release of endogenous growth hormone, a physiological treatment approach has been provided for GHD patients. Compared with traditional exogenous growth hormone replacement therapy, it is more in line with the natural secretion rhythm of the human body and reduces the risk of side effects caused by excessive exogenous hormones. Clinical studies have shown that it can significantly increase the levels of growth hormone in GHD patients, promote bone growth and height increase, and improve their quality of life.

As age increases, the secretion of growth hormone in the human body gradually decreases, leading to a series of age-related changes such as decreased metabolic rate, decreased muscle mass, and increased fat accumulation. By promoting the release of growth hormone, increasing the expression of insulin-like growth factor-1 (IGF-1), regulating metabolic processes, it has a therapeutic effect on age-related diseases. For example, animal experiments have shown that long-term use can increase body weight, improve skeletal muscle mass, decrease the proportion of adipose tissue, and improve insulin resistance and metabolic syndrome in aged rats. In human research, hormone replacement therapy is also used for middle-aged and elderly people, which slows down the aging process by maintaining high levels of growth hormone, reducing body fat, improving sleep, enhancing the immune system, increasing bone density, and improving skin health.

Cachexia is a systemic wasting syndrome caused by serious diseases such as cancer, chronic heart failure, and chronic obstructive pulmonary disease (COPD), characterized by rapid weight loss, muscle atrophy, and increased fat consumption. By stimulating appetite, maintaining energy metabolism balance, and promoting protein synthesis, it has significant therapeutic effects on patients with cachexia. Clinical studies have shown that GHRP-6 injection can increase the food intake and weight of patients with cachexia, reduce metabolic disorders, and improve their quality of life and survival. For example, after continuous use, patients with advanced non-small cell lung cancer showed significant improvements in average weight gain, grip strength, and quality of life scores.

Senile sarcopenia is a disease in which muscle mass and strength decrease with age, seriously affecting the exercise ability and quality of life of the elderly. By promoting the release of growth hormone and increasing the expression of IGF-1, it stimulates muscle protein synthesis, increases lean body mass and muscle strength, thereby improving the motor function of elderly patients with sarcopenia. Clinical studies have shown that elderly patients experience an increase in lean body mass, a decrease in insulin resistance index, and a significant improvement in exercise ability after use.

It can activate hypothalamic arcuate nucleus neurons, upregulate the expression of neuropeptide Y (NPY) and agouti related protein (AgRP), and enhance feeding behavior. Peripheral injection can significantly increase the food intake of rodents and humans, which makes it potentially useful in treating loss of appetite and malnutrition. For example, for patients with decreased appetite caused by illness or treatment, stimulating appetite, increasing energy intake, and improving nutritional status can be used.

GHRP-6 regulates energy metabolism, promotes fat breakdown and glycogen synthesis, and reduces energy expenditure by promoting the release of growth hormone and increasing the expression of IGF-1. This characteristic makes it potentially valuable in the treatment of metabolic syndrome and obesity. For example, animal experiments have shown that it can reduce energy consumption in patients with cachexia, promote protein synthesis, and shift metabolism from catabolic metabolism to synthetic metabolism. In human research, it has also been used to improve metabolic indicators in patients with insulin resistance and metabolic syndrome.

Can promote gastric emptying and gastrointestinal motility, improve gastrointestinal function. This characteristic makes it potentially valuable in the treatment of functional dyspepsia and gastroparesis. For example, studies have shown that injection of GHRP-6 and ghrelin (an endogenous hormone with similar effects to this substance) can significantly increase gastric emptying rate in mice, possibly through receptors on the nitro and cholinergic nerves of the myenteric plexus nervous system.

It can increase cardiac output in patients with heart failure, improve exercise tolerance in COPD patients, and inhibit inflammatory response in patients with chronic respiratory infections. These characteristics make it potentially valuable for the treatment of cardiovascular diseases. For example, research has shown that it can increase cardiac output and stroke volume in patients with chronic heart failure, and improve cardiac function; At the same time, it can also inhibit the inflammatory response of patients with chronic respiratory infections, reduce lung damage and infection risk.